EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling

Yuan Gao, Yu Zhong, Ruifang Guan, Qiuxia Yu, Haiyang Liu, Adili Tuersun, Yanfei Zhang, Liyuan Pang, Xinyi Hu, Guo Ma

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Yuan Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, P…. Hauptthemen laut MEDLINE: Exenatide, Diabetes Mellitus, Type 2, Models, Biological, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although exenatide is approved for patients with type 2 diabetes mellitus (T2DM) with mild to moderate renal impairment, specific dosing guidelines for this population remain undefined. To address this gap, we developed a physiologically based pharmacokinetic model using PK-Sim & MoBi software, integrating target-mediated drug disposition to simulate exenatide's nonlinear pharmacokinetics in normal renal function. The model was extrapolated to renal impairment populations by adjusting physiological parameters and validated against clinical data. The plasma concentrations of exenatide predicted by the established physiologically based pharmacokinetic models for populations with normal renal function and those with renal impairment were in high concordance with the observed values, with fold errors of major pharmacokinetic parameters falling within the 0.5- to 2-fold range. After reducing simulated doses for the renal impairment population to 75%, 50%, and 25% of the 10 μg standard dose, area under the concentration-time curve and Cmax were re-predicted to identify optimal doses that bring this population's pharmacokinetic parameters within the normal ranges. On the basis of our findings, we recommend a model-guided dosing strategy for patients with T2DM with renal impairment, consisting of an initial dose of 2.5 μg twice daily, followed by 5-7.5 μg (mild impairment) or 5 μg (moderate impairment) twice daily for maintenance dose. This study suggests that, compared with patients with T2DM with normal renal function, patients with T2DM with renal impairment should begin at half the initial dose and also receive a reduced maintenance dose. SIGNIFICANCE STATEMENT: Exenatide is approved by the US Food and Drug Administration for patients with type 2 diabetes mellitus with mild to moderate renal impairment, but dosing guidelines are still lacking. This study developed and validated physiologically based pharmacokinetic models of exenatide in renal impairment. These new models close the evidence gap for optimal dosing in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExenatideDiabetes Mellitus, Type 2Models, BiologicalHypoglycemic AgentsRenal InsufficiencyHumansMaleMiddle AgedFemaleDose-Response Relationship, DrugAdultAgedComputer SimulationKidney

Stichwörter der Autor:innen

ExenatideRenal impairmentTarget-mediated drug dispositionphysiologically based pharmacokinetic model

Substanzen

ExenatideHypoglycemic Agents

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, PR China.
  • School of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, PR China. Electronic address: mg0328@fudan.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Gao, Y., Zhong, Y., Guan, R., Yu, Q., Liu, H., Tuersun, A., Zhang, Y., Pang, L., Hu, X., & Ma, G. (2025). Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100199

Vancouver

Gao Y, Zhong Y, Guan R, Yu Q, Liu H, Tuersun A, et al. Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100199

BibTeX
@article{Gao2025,
  author = {Gao, Yuan and Zhong, Yu and Guan, Ruifang and Yu, Qiuxia and Liu, Haiyang and Tuersun, Adili and Zhang, Yanfei and Pang, Liyuan and Hu, Xinyi and Ma, Guo},
  title = {Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100199}
}
Kostenlos starten →